The mesoblast is the embryonic cell layer, also called the mesoderm, that gives rise to muscle, bone, cartilage, blood vessels, blood cells, and connective tissue throughout the body. It forms early in development when a flat disc of cells reorganizes into the three foundational layers that will build every organ and tissue a person has. Of the three germ layers, the mesoblast is the last to appear during embryonic development and, from an evolutionary standpoint, the last to have evolved. Yet its descendants account for an enormous share of what makes a vertebrate body work, from the skeleton holding you upright to the red blood cells carrying oxygen to your brain.
How the Mesoblast Forms
During the first weeks of embryonic life, the fertilized egg divides into a flat sheet of cells. That sheet then undergoes a dramatic rearrangement called gastrulation, during which cells fold inward through a groove known as the primitive streak. Some of those inward-migrating cells slip between the outer layer (ectoderm) and the inner layer (endoderm), forming the middle layer: the mesoblast. This middle layer is not simply deposited in place. Cells actively detach from the surface sheet, change shape, and crawl laterally between the other two layers using specialized adhesion molecules.
One critical molecule in this process is fibronectin, a protein that coats the basement membrane beneath the outer cell layer. Experiments in chick embryos showed that when antibodies blocked fibronectin, cells could still enter the primitive streak but were unable to migrate outward from it. Without fibronectin, the newly ingressed cells lacked the adhesive foothold they needed to crawl into position and spread into a proper mesoblast layer.1PubMed. Microinjection of antifibronectin antibodies in the chicken blastoderm: inhibition of mesoblast cell migration but not of cell ingression at the primitive streak Another molecule, hyaluronate, accumulates on migrating mesoblast cells and appears to facilitate their lateral spread. Early-stage cells that are still de-epithelializing (losing their surface-sheet character) lack hyaluronate, but once they begin moving sideways, it coats their surfaces.2PubMed. Alcian blue staining during the formation of mesoblast in the primitive streak stage chick blastoderm Together, these molecules create a kind of molecular highway that mesoblast cells use to reach their destinations.
From One Layer to Many Tissues
Once established, the mesoblast does not remain a uniform sheet. It subdivides into regions with distinct fates. The paraxial mesoderm, running alongside the developing spinal cord, segments into repeating blocks called somites. Those somites produce the vertebral column, ribs, skeletal muscle, and part of the skin’s deeper layers. Within each somite, a region called the sclerotome specifically generates the bones of the spine and contributes to tendons, blood vessels including the dorsal aorta, and even the protective membranes around the brain and spinal cord.3PubMed Central. Understanding paraxial mesoderm development and sclerotome specification for skeletal repair
The lateral plate mesoderm, meanwhile, splits into two sheets that give rise to the heart, blood vessels, smooth muscle of the gut, and the lining of body cavities. And a specialized mesodermal population called the intermediate mesoderm forms the kidneys and much of the reproductive system. So while the article’s title highlights muscle, bone, and blood, the mesoblast’s true portfolio is broader: it builds most of the body’s structural and circulatory infrastructure.
Where Blood Cells Come From
Blood cells trace their ancestry to the mesoblast through a fascinating intermediate. During early development, certain mesodermal cells give rise to what researchers call the hemangioblast, a precursor that can produce both blood cells and the cells lining blood vessels. In mouse embryos, the hemangioblast is enriched in specific cell populations within the posterior primitive streak, while in zebrafish it appears in the ventral mesoderm.4PubMed Central. Molecular and developmental biology of the hemangioblast The concept is elegant: a single progenitor cell type seeds both the tubes that carry blood and the cells that flow through them.
That said, the picture has gotten more complicated. Recent work suggests the hemangioblast does not account for all endothelial and blood cell lineages. Some blood-forming cells appear to arise from distinct mesodermal populations that bypass the hemangioblast stage entirely. The basic principle that blood cells originate from the mesoblast still holds, but the routes from mesoderm to mature blood are more varied than a single progenitor pathway would suggest.
The Bone Marrow Niche and Blood Cell Support
The mesoblast’s involvement with blood does not end after embryonic development. In adults, bone marrow is the primary factory for new blood cells, and the marrow environment depends on mesenchymal stromal cells, the adult descendants of the embryonic mesoblast. These stromal cells form a scaffolding within the marrow that nurtures blood-forming stem cells. Their therapeutic value rests on three broad capabilities: they modulate the immune system, they help regenerate damaged tissue, and they support blood cell production.5PubMed Central. Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders
Research has mapped out a hierarchy among these marrow stromal cells. Certain progenitors marked by the surface protein Sca1 sit near blood vessels within the trabecular bone region, wrapped around the sinusoidal vessels that thread through the marrow. These give rise to intermediate progenitors (marked by CD146) and then to mature bone-forming progenitors (marked by CD166) that settle along the inner bone surface.6Nature Communications. Identification of a common mesenchymal stromal progenitor for the adult haematopoietic niche In essence, the mesoblast’s legacy in adult bone marrow is a layered system of support cells, each type occupying a specific neighborhood and performing a specific job to keep blood production running.
This relationship has clinical implications. When patients undergo cord-blood transplants, the speed at which donated blood-forming stem cells “engraft” and begin producing new blood cells can be painfully slow. In a trial that co-cultured cord blood with mesenchymal stromal cells before transplantation, the expanded cord blood led to neutrophil engraftment in a median of 15 days compared to 24 days with standard unmanipulated cord blood. Platelet engraftment similarly accelerated.7PubMed Central. Cord-blood engraftment with ex vivo mesenchymal-cell coculture The mesenchymal cells essentially primed the blood stem cells for faster recovery, which for a patient with a compromised immune system can mean the difference between a dangerous infection window and a manageable one.
How Stiffness Steers Cell Fate
One of the more surprising discoveries about mesoblast-derived stem cells is that their fate depends on the physical stiffness of their surroundings, not just chemical signals. Mesenchymal stem cells grown on soft surfaces that mimic brain tissue tend to become nerve-like cells. On surfaces mimicking the stiffness of muscle, they lean toward muscle. On rigid surfaces resembling bone, they differentiate into bone-forming cells. The cells literally feel their environment and adjust their identity accordingly.8PubMed Central. Role of mechanical factors in fate decisions of stem cells
This mechanosensing works through the cytoskeleton, the internal scaffolding of the cell. When a cell pushes against a stiff surface, tension travels through adhesion proteins anchored in the cell membrane, through the cytoskeletal network, and ultimately into the nucleus, where it influences which genes get turned on.9PubMed Central. Stem Cell Differentiation is Regulated by Extracellular Matrix Mechanics The stiffness of the extracellular matrix is transduced into gene expression changes through these adhesion and cytoskeletal proteins.10PubMed Central. Mechanism of regulation of stem cell differentiation by matrix stiffness The practical upshot is significant for anyone trying to grow replacement tissues in a lab: getting the chemistry right is only half the problem. If the scaffold or culture surface has the wrong stiffness, the cells may head down an entirely different developmental path.
The Mesoblast in Evolutionary Context
Not every animal has a mesoblast. Jellyfish and comb jellies, members of the phyla Cnidaria and Ctenophora, are diploblastic: they have only two germ layers, ectoderm and endoderm, and manage just fine building relatively simple body plans from those two layers alone. The mesoderm appears to have been the final germ layer to evolve, and its gene expression program is still induced after those of the ectoderm and endoderm during development.11PubMed Central. Spatiotemporal transcriptomics reveals the evolutionary history of the endoderm germ layer
The evolutionary transition from two layers to three was a pivotal moment in animal history. According to one framework, the key innovation was the ability of cells to undergo epithelial-to-mesenchymal transformation, where cells break free from an organized sheet and become mobile, individual cells that can invade the space between the existing two layers. This required new kinds of extracellular matrices that could support that transformation.12PubMed Central. ‘Biogeneric’ developmental processes: drivers of major transitions in animal evolution Once animals could produce a third layer of mobile, multipotent cells, they gained access to an entirely new set of body structures: internal skeletons, muscular walls, closed circulatory systems, complex kidneys. The explosion of animal body plans in the Cambrian period is, in large part, a story about what became possible once the mesoblast existed.
Mesenchymal Stem Cells in Regenerative Medicine
Because mesoblast-derived mesenchymal stem cells can produce bone, cartilage, fat, and muscle, and because they dampen immune reactions, they have become one of the most studied cell types in regenerative medicine. Hundreds of clinical trials have explored their use for conditions ranging from heart failure to autoimmune disease to orthopedic injuries.
In the cardiac space, a randomized trial tested mesenchymal precursor cells injected directly into the heart muscle of patients with chronic heart failure. In the full analysis population of 537 patients, the treatment reduced the risk of heart attack or stroke by about 58%. In a subgroup of patients with elevated inflammatory markers, the reduction was even larger, around 75%.13PubMed Central. Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure These results are striking, though like all single-trial findings they need confirmation before they reshape standard care.
For bone repair, researchers have worked on ways to grow large quantities of mesenchymal stem cells efficiently. One approach uses tiny beads called microcarriers as a growth surface. Human fetal mesenchymal stem cells grown on microcarriers expanded roughly 12- to 16-fold, compared to only 4- to 6-fold with traditional flat-dish culture. When these microcarrier-expanded cells were then seeded onto three-dimensional scaffolds, they deposited about 64% more calcium and formed roughly 47% more bone volume than their conventionally grown counterparts.14PubMed Central. Microcarrier culture for efficient expansion and osteogenic differentiation of human fetal mesenchymal stem cells The cells did not just grow faster on the beads; they became better at making bone, suggesting that the three-dimensional growth environment primed them for their eventual task.
A newer frontier is bioprinting vascular structures from mesodermal progenitor cells derived from human induced pluripotent stem cells. Researchers have generated self-organizing “mother vessels” through bioprinting and then connected them to microvessels sprouting from organoids, creating interconnected vascular networks in the lab.15PubMed Central. Generation of Self-Organizing Macrovascular Constructs by Bioprinting Human iPSC-Derived Mesodermal Progenitor Cells The goal is eventually to build tissues thick enough to survive transplantation, where every cell sits close enough to a blood vessel to receive oxygen and nutrients.
Safety Concerns and Open Questions
Because mesenchymal stem cells can differentiate into multiple tissue types, a natural worry is that transplanted cells might form tissue in the wrong place: bone where there should be soft tissue, for example. Clinical data so far has been reassuring on this front. In a trial of remestemcel-L (a mesenchymal cell product) for severe graft-versus-host disease in children, no confirmed cases of ectopic tissue formation were observed. The study did note a theoretical risk of patients developing antibodies against the transplanted cells, since they come from a donor, but this did not translate into clinical problems in the trial population.16JAMA. Remestemcel-L-rknd for Steroid-Refractory Acute Graft-vs-Host Disease in Pediatric Patients
Another challenge is scaling up. Growing enough cells for therapeutic doses while keeping them healthy and functional is not trivial. Mesenchymal stem cells that have been passaged many times in culture can lose their regenerative capacity, and the cells themselves age. In fact, the reduced ability of adult stem cell populations to regenerate is considered one of the main contributors to human aging. As mesenchymal stem cells become senescent, they lose their capacity to divide, their ability to differentiate narrows, and they begin secreting inflammatory signals that can harm surrounding tissue.17PubMed Central. Aging of mesenchymal stem cell: machinery, markers, and strategies of fighting This presents a double problem: the patients who most need regenerative therapy (older adults with worn-out joints or weakening bones) are the ones whose own mesenchymal stem cells are least capable of doing the job, and donor cells must be carefully managed to avoid the same aging fate in the dish.
Lab-Grown Marrow and Blood Production
One of the more creative uses of mesoblast-derived cells involves recreating the bone marrow environment outside the body. Researchers have built three-dimensional “micromarrows,” tiny aggregates of blood-forming stem cells co-cultured with mesenchymal stromal cells. When stromal cells were maintained in these three-dimensional clusters rather than on flat dishes, they expressed significantly higher levels of the signaling factors that normally sustain blood stem cells within the marrow.18PubMed. Micromarrows–three-dimensional coculture of hematopoietic stem cells and mesenchymal stromal cells The shape of the environment mattered: flat culture conditions failed to activate the same support programs that three-dimensional aggregates triggered.
This work ties back to the mechanosensing principle described earlier. Mesenchymal cells respond to the geometry and stiffness of their surroundings at every stage of life, from the first crawling movements of mesoblast cells across a fibronectin-coated basement membrane in the embryo to the behavior of adult stromal cells shaped by the architecture of a lab-built scaffold. The consistency of this theme is one reason so many tissue-engineering strategies now prioritize getting the physical environment right before worrying about the chemical cocktail.
Regeneration Across Species
Humans are not particularly good at regeneration, and the limits of our mesoblast-derived tissues are part of the reason. When you fracture a bone, mesenchymal progenitors in the bone lining and marrow can rebuild it. But lose a finger, and the regrowth stops at wound healing. The axolotl, by contrast, can regrow an entire limb. After amputation, the axolotl generates a mass of regeneration-competent progenitor cells called a blastema at the wound site. Multiple cell types from the mature limb stump contribute to this blastema, and the cells re-establish spatial patterning to produce a limb with the correct proportions and structure.19PubMed Central. The axolotl limb blastema: cellular and molecular mechanisms driving blastema formation and limb regeneration in tetrapods
What makes the axolotl blastema so interesting from a mesoblast perspective is that many of the contributing cells are mesodermal derivatives: muscle fibers, connective tissue cells, skeletal progenitors. In the axolotl, these cells can revert to a more stem-like state and then re-differentiate into the specific tissues needed. In humans, mesenchymal stem cells retain some of this flexibility, but the signals that would coordinate a full-scale limb rebuild are absent. Understanding the difference between the axolotl’s permissive environment and the human wound environment is one of the long-term goals of regenerative biology. The mesoblast laid down the same foundational toolkit in both species hundreds of millions of years ago; the divergence lies in how that toolkit is reactivated after injury.
Cartilage and the Mesenchymal Progenitor Pipeline
Bone gets most of the attention when people think about the skeleton, but cartilage formation is an equally important mesoblast-driven process, and it happens first. During embryonic limb development, mesenchymal progenitor cells in the limb bud first condense into cartilage templates that later ossify into bone through a process called endochondral ossification. Research deleting the VHL gene in limb bud mesenchymal progenitors found that, even without this gene, the cells still differentiated into chondrocytes on schedule.20PubMed Central. Loss of VHL in mesenchymal progenitors of the limb bud alters multiple steps of endochondral bone development The initial step of becoming cartilage was robust enough to proceed even when a key oxygen-sensing pathway was disrupted. Later steps of converting that cartilage into mature bone, however, were altered, suggesting that different stages of the mesenchymal-to-bone pipeline are controlled by different molecular switches.
This matters clinically because osteoarthritis, the most common joint disease, involves the breakdown of cartilage that the body struggles to replace. Adult mesenchymal stem cells can be coaxed into producing cartilage in the lab, but getting them to form cartilage that is mechanically durable enough to survive in a weight-bearing joint remains an unsolved problem. The embryonic pipeline from mesenchymal progenitor to functional cartilage to bone involves a precisely timed sequence of signals, and recreating that sequence outside the body has proven far harder than simply pushing cells down a cartilage path.